Novel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Novel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants"

Transcription

1 Office of AIDS Research Novel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants L. Jean Patterson, PhD Office of AIDS Research, NIH February 7, 2017

2 Office of AIDS Research OAR Responsibilities -Coordinate the scientific, budgetary, legislative, and policy elements of NIH HIV/AIDS research. -Develop a strategic plan as a roadmap for allocation of funds -Receive and disperse across NIH all funds for HIV/AIDS research -Ensure that research dollars are invested in the highest priority areas of scientific opportunity in the global fight against HIV/AIDS

3 Office of AIDS Research Overarching High Priority Areas Reduce the Incidence of HIV/AIDS Next Generation HIV Therapies Research Toward a Cure HIV-Associated Comorbidities, Complications, & Coinfections Less Toxic and Longer Lasting Treatment Basic Research, Health Disparities, Behavioral & Social Sciences, and Training Optimize Engagement and Retention

4 Office of AIDS Research IMPAACT Network Vaccine Task Force Outcomes -Immune responses to candidate vaccines have been shown to be of higher magnitude and durability in infants compared to adults. -Immune modulation in infancy and childhood may enhance the efficacy of products administered later in life. Gaps exist in our understanding of infant immunity.

5 Office of AIDS Research IMPAACT Vaccine Task Force Outcomes-cont. 3 recommendations: -Known surrogates of immune protection in pediatric cohorts could and should be studied using existing samples. -Efficacy studies are not feasible at this time within IMPAACT. -However, a Vaccine Working Group soon will be established to develop and implement a rolling protocol design within a 3-year timeframe to evaluate safety and immunogenicity of multiple candidate HIV vaccine products and other agents/products to prevent HIV transmission.

6 Office of AIDS Research Criteria for selection of candidate vaccine products Must be: Unencumbered by Industry/Pharma partners Already tested or soon to enter Phase I clinical trial in adults GMP product on the shelf or ready in the next 6-12 months Enough available product for infant studies

7 Overall Summary of Available Products 1. DNA/Protein: PDPHV (HVTN protocol 124) Shan Lu, UMass 2. CH505 Envelope Clade C Gp120 lineage design proteins; T/F, Wk 53, 78, 100 envelopes (HVTN 115 enrolling soon) Bart Haynes, Duke 3. Env proteins: -BG505 SOSIP Gp140 trimer, developed from a Clade A, infant T/F virus (planned as part of an HVTN adjuvants trial) John Moore, Cornell -Gp145 trimeric Clade C envelope, DAIDS/MHRP -Gp140 fold-on trimer, Clade C envelope, MHRP

8 Overall Summary of Available Products 1. DNA/Protein: PDPHV (HVTN protocol 124) Shan Lu, UMass 2. CH505 Envelope Clade C Gp120 lineage design proteins; T/F, Wk 53, 78, 100 envelopes (HVTN 115 enrolling soon) Bart Haynes, Duke 3. Env proteins: -BG505 SOSIP Gp140 trimer, developed from a Clade A, infant T/F virus (planned as part of an HVTN adjuvants trial) John Moore, Cornell -Gp145 trimeric Clade C envelope, DAIDS/MHRP -Gp140 fold-on trimer, Clade C envelope, MHRP

9 Office of AIDS Research A. DNA/Protein prime-boost or co-immunization DNA prime/protein boost using multigene polyvalent HIV vaccine (DP6-001 clinical trial) Shan Lu, UMass -6 DNA plasmids encoding gp120 genes from primary HIV envelopes; clades A, B(2), C, E, and gag gene from clade C subtype -5 Gp120 proteins matching same clades as DNA formulated in QS21 -Healthy volunteers were enrolled in Phase I trial at UMMS -DNA (ID or IM) at Wk 0, 4, 12; protein boosts (IM) at Wk 20, 28, IM

10 High level Env-Specific Serum IgG Responses in DP6-001 Vaccinees (quickly rising to the level of level following a single protein boost) gp120 specific IgG titers gp120 specific IgG titers (log 10 ) Group A (DNA-ID x 3 + protein x 2) Group B (DNA-IM x 3 + protein x 2) gp120 specific IgG titers Weeks g p s p e c ific a n tib o d y r e s p o n s e in D P v a c cweeks in e e g p s p e c ific Ig G tite r s G ro u p A G ro u p B W e e k Long lasting IgG titers for the study period Wang, S., et. al. Vaccine, 2008

11 A panel of human mabs with potent and cross reactive (against 3-4 subtypes) ADCC and ADCP activities from DP6-001 volunteers Matthew R. Costa et al. J. Virol. 2016;90:

12 PDPHV (HVTN protocol 124) PD (DNA vaccines produced from E coli) gp120-a, gp120-b, gp120-c, gp120-ae, Gag-C 0.4 mg each for a total of 2 mg at each immunization IM injection PP (protein vaccines produced from CHO) gp120-a, gp120-b, gp120-c, gp120-ae 100 mcg each for a total of 400 mcg at each immunization Adjuvant GLA-SE (from IDRI) Two possible immunization schedules Sequential: DNA: months 0, 2, 4 and protein months 6, 8 Simultaneous: DNA + protein: months 0, 2, 4, 6, 8 Shan Lu, UMass

13 Infant versus adults rhesus macaques immunized with DNA prime-rad5 VRC vaccine more evidence that DNA priming elicits high titered antibodies VRC DNA prime-rad5 boost regimes in HVTN505 adult macaques infant macaques Vincent Han, Sallie Permar, Koen Von Rompay, Bart Haynes

14 Study Summary When using DNA as a priming immunogen, infant rhesus macaques responded better than adult rhesus macaques with regard to binding and neutralizing antibody induction.

15 Overall Summary of Available Products 1. DNA/Protein: PDPHV (HVTN protocol 124) Shan Lu, UMass 2. CH505 Envelope Clade C Gp120 lineage design proteins; T/F, Wk 53, 78, 100 envelopes (HVTN 115 enrolling soon) Bart Haynes, Duke 3. Env proteins: -BG505 SOSIP Gp140 trimer, developed from a Clade A, infant T/F virus (planned as part of an HVTN adjuvants trial) John Moore, Cornell -Gp145 trimeric Clade C envelope, DAIDS/MHRP -Gp140 fold-on trimer, Clade C envelope, MHRP

16 Office of AIDS Research B. Envelope proteins lineage design CH505 Envelope Clade C Gp120 proteins; T/F, Wk 53, 78, 100 envelopes (HVTN 115 enrolling soon) Bart Haynes, Duke -Isolated over time in an individual who went on develop broadly neutralizing antibodies - Liao, et. al., Nature, Envs selected coincided with emergence of lineages able to develop into bnabs -Need to re-purify Wk 53 protein before use as immunogen -May see accelerated development of bnabs in infants -Plan to use GLA-SE adjuvant (IDRI) in adult trial -Sallie Permar proposal to IMPAACT (CAP523)

17 Overall Summary of Available Products 1. DNA/Protein: PDPHV (HVTN protocol 124) Shan Lu, UMass 2. CH505 Envelope Clade C Gp120 lineage design proteins; T/F, Wk 53, 78, 100 envelopes (HVTN 115 enrolling soon) Bart Haynes, Duke 3. Env proteins: -BG505 SOSIP Gp140 trimer, developed from a Clade A, infant T/F virus (planned as part of an HVTN adjuvants trial) John Moore, Cornell -Gp145 trimeric Clade C envelope, DAIDS/MHRP -Gp140 fold-on trimer, Clade C envelope, MHRP

18 Office of AIDS Research C. Envelope proteins as part of a boosting strategy or alone BG505 SOSIP Gp140 trimer, developed from a Clade A, infant T/F virus (planned as part of an HVTN adjuvants trial) John Moore, Cornell -In rabbits and NHPs, elicits high titered homologous Tier 2 neutralizing antibodies, but unfortunately not Tier 2 heterologous neuts, which are desired -Later, more stabilized versions of this trimer have been developed in the laboratory, known to elicit fewer anti-v3 antibodies and presumably better Tier 2 neutralizing antibodies - Use as a boosting immunogen in future strategies Sanders, et. al., J. Virol. 2002; Sanders, et. al., Plos Pathogens 2013; de Taeye, et. al., Cell 2015

19 Vaccination of neonates with soluble CH505 near-native SOSIP trimers Study goal: To determine whether the neonate antibody repertoire can recognize bnab epitopes on HIV-1 Env with trimer vaccination. Env TF TF TF w53 w78 w100 Timept (week) Adults N=4 Neonates Infants **Some data after week 20 are still pending for adults N=3

20 Summary CH505 chimeric trimer vaccination of infants elicited higher binding, CD4 blocking, as well as tier 1 neutralizing antibodies. Studies are underway with stabilized chimeric CH505 sequential trimers with the V3 loop and the gp41 unexposed to compare immunogenicity of closed trimers versus open trimers in infants.

21 Overall Summary of Available Products 1. DNA/Protein: PDPHV (HVTN protocol 124) Shan Lu, UMass 2. CH505 Envelope Clade C Gp120 lineage design proteins; T/F, Wk 53, 78, 100 envelopes (HVTN 115 enrolling soon) Bart Haynes, Duke 3. Env proteins: -BG505 SOSIP Gp140 trimer, developed from a Clade A, infant T/F virus (planned as part of an HVTN adjuvants trial) John Moore, Cornell -Gp145 trimeric Clade C envelope, DAIDS/MHRP -Gp140 fold-on trimer, Clade C envelope, MHRP

22 Office of AIDS Research C. Envelope proteins as part of a boosting strategy or alone cont. Gp145 trimeric Clade C envelope DAIDS/MHRP -Was intended as a boost protein for the replicating Tian Tian vaccine in China, but unsure of status of this trial Gp140 fold-on trimer, Clade C envelope MHRP -Not native-like, but has been in adults as a boost for the APPROACH study

23 Office of AIDS Research D. Longer shot candidates -CE p24 DNA prime/p55 Gag DNA IL-12 boost and/or boost with available Envelope protein (Mullins) Q Clade B Gp120 envelope protein (BG ) (Haynes) Q Chimp AdC6/C7 Clade C Gp120 (Ertl) - TBD -ChAdOx1 + HIV consv6 (Hanke) TBD -mrna - TBD

24 Office of AIDS Research Acknowledgements OAR, OD IMPAACT BioQual Maureen Goodenow Sharon Nachman Mark Lewis Peter Kim John Sleasman Bonnie Mathieson Duke UC Davis DAIDS, NIAID Barton Haynes Koen Von Rompay Mary Marovich Sallie Permar Kevin Ryan Vincent Han Michael Pensiero Kevin Saunders Sheryl Zwerski David Montefiori Carl Dieffenbach Rob Parks UMass Shan Lu Beth Israel Deaconess Medical Center Sampa Santra

25 NIH Turning Discovery Into Health 30

Virus Panels for Assessing Vaccine-Elicited Neutralizing Antibodies

Virus Panels for Assessing Vaccine-Elicited Neutralizing Antibodies Virus Panels for Assessing Vaccine-Elicited Neutralizing Antibodies Michael Seaman, Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Harvard Medical School J. Virol.

More information

HVTN P5 Vaccine Trials

HVTN P5 Vaccine Trials HVTN P5 Vaccine Trials Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali, Rwanda 16-17 March 2015 HVTN Mission

More information

HIV Prophylactic Vaccine Development Program

HIV Prophylactic Vaccine Development Program HIV Prophylactic Vaccine Development Program Maria Grazia Pau Senior Director, Compound Development Team Leader, Janssen AVAC Webinar, 28 April 2017 HIV vaccine R&D programs: Current Collaborators (in

More information

HIV and Challenges of Vaccine Development

HIV and Challenges of Vaccine Development Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV and Challenges of Vaccine Development Richard A. Koup, MD INTEREST

More information

HVTN Laboratory Program: Immunogenicity and Research Assays

HVTN Laboratory Program: Immunogenicity and Research Assays HVTN Laboratory Program: Immunogenicity and Research Assays Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali,

More information

Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study

Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study Note: I have added some clarifying comments to the slides -- please click on Comments under View to see them. Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a

More information

Boosts Following Priming with gp120 DNA

Boosts Following Priming with gp120 DNA Neutralizing Antibody Responses Induced with V3-scaffold Protein Boosts Following Priming with gp120 DNA Susan Zolla-Pazner NYU School of Medicine Problems with Whole Env Immunogens Poor induction of Abs

More information

Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys

Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Dan H. Barouch, M.D., Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Ragon Institute of MGH, MIT,

More information

Ongoing HVTN Trials (Enrolling, In Follow-up, and in Long Term Follow-up)

Ongoing HVTN Trials (Enrolling, In Follow-up, and in Long Term Follow-up) Ongoing HVTN Trials (, In, and in ) HVTN 085 90 HVTN VRC rad5 multiclade 02/2012 Boston - Brigham; Chicago; Nashville; New York - NYBC; New York - NYBC - Bronx; Philadelphia; Rochester; San Francisco;

More information

We are IntechOpen, the first native scientific publisher of Open Access books. International authors and editors. Our authors are among the TOP 1%

We are IntechOpen, the first native scientific publisher of Open Access books. International authors and editors. Our authors are among the TOP 1% We are IntechOpen, the first native scientific publisher of Open Access books 3,350 108,000 1.7 M Open access books available International authors and editors Downloads Our authors are among the 151 Countries

More information

A global approach to HIV-1 vaccine development

A global approach to HIV-1 vaccine development A global approach to HIV-1 vaccine development The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Published Version Accessed

More information

Adjuvant-Specific Serum Cytokine Profiles in the Context of a DNA Prime-Protein Boost HIV-1 Vaccine: A Dissertation

Adjuvant-Specific Serum Cytokine Profiles in the Context of a DNA Prime-Protein Boost HIV-1 Vaccine: A Dissertation University of Massachusetts Medical School escholarship@umms GSBS Dissertations and Theses Graduate School of Biomedical Sciences 4-29-2013 Adjuvant-Specific Serum Cytokine Profiles in the Context of a

More information

Alabama Vaccine Research Clinic. Clinical Research Trials Guide: Vaccines & Microbicides. University of Alabama at Birmingham

Alabama Vaccine Research Clinic. Clinical Research Trials Guide: Vaccines & Microbicides. University of Alabama at Birmingham Alabama Vaccine Research Clinic Clinical Research Trials Guide: Vaccines & Microbicides University of Alabama at Birmingham Introduction About the AVRC Since 1994, the Alabama Vaccine Research Clinic (AVRC)

More information

The humoral immune responses to IBV proteins.

The humoral immune responses to IBV proteins. The humoral immune responses to IBV proteins. E. Dan Heller and Rosa Meir The Hebrew University of Jerusalem, Israel COST FA1207 meeting WG2 + WG3, Budapest, Jan. 2015 1 IBV encodes four major structural

More information

Immunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group

Immunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group report Immunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group John Mascola, C Richter King & Ralph Steinman on behalf of a Working Group convened by the Global HIV

More information

The History of HIV Vaccine Development

The History of HIV Vaccine Development The History of HIV Vaccine Development a short story on 30 years of research å Dr. Jill Gilmour International AIDS Vaccine Initiative Barcelona, 6 October 2013 IAVI is a product-development partnership

More information

IAVIReport. Drug-Resistant HIV on the Rise. Pediatric HIV Vaccine Trials. A Conversation with Thomas Hope VOLUME 21, ISSUE 4

IAVIReport. Drug-Resistant HIV on the Rise. Pediatric HIV Vaccine Trials. A Conversation with Thomas Hope VOLUME 21, ISSUE 4 VOLUME 21, ISSUE 4 IAVIReport The Publication on AIDS Vaccine Research WWW.IAVIREPORT.ORG VOLUME 21, ISSUE 4 2017 Pediatric HIV Vaccine Trials A Conversation with Thomas Hope Drug-Resistant HIV on the

More information

TOWARDS A UNIVERSAL INFLUENZA VIRUS VACCINE

TOWARDS A UNIVERSAL INFLUENZA VIRUS VACCINE TOWARDS A UNIVERSAL INFLUENZA VIRUS VACCINE Peter Palese Icahn School of Medicine at Mount Sinai New York OPTIONS IX 8-26-16 ISIRV - Options IX for the Control of Influenza Peter Palese, PhD Professor

More information

Heterologous Tier 1 R5 SHIV-C Challenges: Correlates of Protection

Heterologous Tier 1 R5 SHIV-C Challenges: Correlates of Protection Heterologous Tier 1 R5 SHIV-C Challenges: Correlates of Protection Enterprise Meeting: The Appropriate Use of Tiered Virus Panels when Assessing HIV-1 Vaccine-elicited Neutralizing Antibodies" July 7 th,

More information

NIH Public Access Author Manuscript Nature. Author manuscript; available in PMC 2009 July 1.

NIH Public Access Author Manuscript Nature. Author manuscript; available in PMC 2009 July 1. NIH Public Access Author Manuscript Published in final edited form as: Nature. 2009 January 1; 457(7225): 87 91. doi:10.1038/nature07469. Immune Control of an SIV Challenge by a T Cell-Based Vaccine in

More information

H5N1 and H7 LAIV-IAV Prime-Boost Studies

H5N1 and H7 LAIV-IAV Prime-Boost Studies NIAID H5N1 and H7 LAIV-IAV Prime-Boost Studies Kanta Subbarao, MD, MPH NIAID, NIH The LID Pandemic Influenza Vaccine Program Program: CRADA with MedImmune Clinical Trials: Center for Immunization Research,

More information

DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED

DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED Viv Peut Kent Laboratory, University of Melbourne, Australia WHY ENVELOPE? Env subject to both humoral and cellular immune responses Perhaps

More information

The RV144 vaccine trial in Thailand demonstrated an estimated

The RV144 vaccine trial in Thailand demonstrated an estimated Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion S. Munir Alam, a Hua-Xin Liao, a Georgia D. Tomaras, a Mattia Bonsignori,

More information

2005 LANDES BIOSCIENCE. DO NOT DISTRIBUTE.

2005 LANDES BIOSCIENCE. DO NOT DISTRIBUTE. [Human Vaccines 1:2, 45-60; March/April 2005]; 2005 Landes Bioscience Review Role of Neutralizing Antibodies in Protective Immunity Against HIV Indresh K. Srivastava* Jeffrey B. Ulmer Susan W. Barnett

More information

Spike Trimer RNA. dsdna

Spike Trimer RNA. dsdna Spike Trimer RNA dsdna Spike Trimer RNA Spike trimer subunits xxx gp120: receptor and coreceptor binding xxxxxxx gp41: membrane anchoring and target cell fusion dsdna Spike Trimer HIV gp120 binds to host

More information

T cell Vaccine Strategies for HIV, the Virus. With a Thousand Faces

T cell Vaccine Strategies for HIV, the Virus. With a Thousand Faces JVI Accepts, published online ahead of print on 13 May 2009 J. Virol. doi:10.1128/jvi.00114-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

More information

Development of live attenuated pediatric RSV vaccines

Development of live attenuated pediatric RSV vaccines Development of live attenuated pediatric RSV vaccines Laboratory of Infectious Diseases, NIAID, NIH (Ursula Buchholz, Peter Collins) Center for Immunization Research, JHU (Ruth Karron) Infant with RSV

More information

Broadly Neutralizing Antibodies for HIV Eradication

Broadly Neutralizing Antibodies for HIV Eradication DOI 10.1007/s11904-016-0299-7 HIV PATHOGENESIS AND TREATMENT (AL LANDAY, SECTION EDITOR) Broadly Neutralizing Antibodies for HIV Eradication Kathryn E. Stephenson 1,2 & Dan H. Barouch 1,2 # The Author(s)

More information

7/14/2014. Multiple immune effector mechanisms contribute to protection influenza. What is a correlate of protection?

7/14/2014. Multiple immune effector mechanisms contribute to protection influenza. What is a correlate of protection? What is a correlate of protection? Immunological Assessment of Influenza Vaccines and Correlates of Protection Jacqueline Katz Influenza Division Centers for Disease Control and Prevention Defined immune

More information

What are ADCC antibodies? Work on influenza ADCC antibodies Greenberg et al, Hashimoto et al. First describes Fluspecific

What are ADCC antibodies? Work on influenza ADCC antibodies Greenberg et al, Hashimoto et al. First describes Fluspecific 14/7/214 Acknowledgement antibodies against diverse influenza strains: Implications for universal vaccination Sinth Jegaskanda PhD Prof Stephen Kent University of Melbourne What are antibodies? Work on

More information

Active and Passive Immunization for Avian Influenza Virus Infections

Active and Passive Immunization for Avian Influenza Virus Infections NIAID Active and Passive Immunization for Avian Influenza Virus Infections Kanta Subbarao, MD, MPH Laboratory of Infectious Diseases NIAID, NIH Immortalizing H5 HA-Specific Memory B Cells Collection of

More information

on April 26, 2018 by guest

on April 26, 2018 by guest JVI Accepted Manuscript Posted Online 20 July 2016 J. Virol. doi:10.1128/jvi.00853-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10 11 Induction of heterologous

More information

Malaria parasite vaccine development Strategies & Targets

Malaria parasite vaccine development Strategies & Targets Malaria parasite vaccine development Strategies & Targets Tulane University Ahmed Aly Most malaria disease deaths are among children and pregnant women A child or a pregnant woman dies of malaria nearly

More information

Antigenic and Immunogenic Study of Membrane-Proximal External Region-Grafted gp120 Antigens by a DNA Prime-Protein Boost Immunization Strategy

Antigenic and Immunogenic Study of Membrane-Proximal External Region-Grafted gp120 Antigens by a DNA Prime-Protein Boost Immunization Strategy JOURNAL OF VIROLOGY, Apr. 2007, p. 4272 4285 Vol. 81, No. 8 0022-538X/07/$08.00 0 doi:10.1128/jvi.02536-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Antigenic and Immunogenic

More information

Heterologous Prime-Boost & Adjuvanted Env Protein HIV Vaccine Approaches

Heterologous Prime-Boost & Adjuvanted Env Protein HIV Vaccine Approaches Heterologous Prime-Boost & Adjuvanted Env Protein HIV Vaccine Approaches Susan W. Barnett WHO-NIAID Meeting on HIV, Malaria, and TB Vaccines April 17-18, 2012 Rockville, MD Background & vision of HIV vaccine

More information

It has been 25 years since HIV-1 was identified as the causative

It has been 25 years since HIV-1 was identified as the causative Vol 4j2 October 8jdoi:.38/nature732 Challenges in the development of an HIV-1 vaccine Dan H. Barouch 1 The development of a safe and effective human immunodeficiency virus (HIV)-1 vaccine is a critically

More information

ImmTACs, a new class of immune-oncology therapeutic

ImmTACs, a new class of immune-oncology therapeutic 1 ImmTACs, a new class of immune-oncology therapeutic Immunocore the world s leading soluble T cell receptor company Immunocore is based near Oxford in the UK Has a unique platform of biologics based on

More information

Target Design and Immunogenicity

Target Design and Immunogenicity Target Design and Immunogenicity 03-18-2013 Vidadi Yusibov New Cells, New Vaccines VII: From Protein to Product Vaccine Products Conventional vaccines: Inactivated Live, attenuated Toxoid Recombinant Subunit

More information

Vaccine Trial Centre. Established in1984 Funded by WHO on Control of Diarrhea Diseases Full operation in1986

Vaccine Trial Centre. Established in1984 Funded by WHO on Control of Diarrhea Diseases Full operation in1986 Vaccine Trial Centre Established in1984 Funded by WHO on Control of Diarrhea Diseases Full operation in1986 Past 29 Years of Research Experiences Cholera Vaccine Killed whole cell and B sub-unit oral vaccine

More information

Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination

Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination M. Juliana McElrath 1, * and Barton F. Haynes 2, * 1 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research

More information

Application of Reverse Genetics to Influenza Vaccine Development

Application of Reverse Genetics to Influenza Vaccine Development NIAID Application of Reverse Genetics to Influenza Vaccine Development Kanta Subbarao Laboratory of Infectious Diseases NIAID, NIH Licensed Vaccines for Influenza Principle: Induction of a protective

More information

The HIV Prevention Toolbox: More Tools Needed

The HIV Prevention Toolbox: More Tools Needed The HIV Prevention Toolbox: More Tools Needed Z Mike Chirenje MD FRCOG University of Zimbabwe, College of Health Sciences, Dept. of Obstetrics and Gynaecology Avondale, Harare, Zimbabwe chirenje@uz-ucsf.co.zw

More information

WHO INFLUENZA VACCINE RECOMMENDATION

WHO INFLUENZA VACCINE RECOMMENDATION WHO INFLUENZA VACCINE RECOMMENDATION Strategic Advisory Group of Experts (SAGE) on Immunization SAGE Working Group on Influenza Vaccine and Immunization 1 Evidence Evaluation: Conceptual Matrix Target

More information

Reviewing the Clinical Development of Zika and Chikungunya Vaccines

Reviewing the Clinical Development of Zika and Chikungunya Vaccines Reviewing the Clinical Development of Zika and Chikungunya Vaccines Stephen J. Thomas, MD Division of Infectious Diseases State University of New York Upstate Medical University October 2017 Discussion

More information

Identification and Characterization of CD4 T cells actively transcribing HIV RNA in Peripheral Blood

Identification and Characterization of CD4 T cells actively transcribing HIV RNA in Peripheral Blood Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Identification and Characterization of CD4 T cells actively transcribing

More information

Application. Animal Models in Preclinical Evaluation of sanofi pasteur Flavivirus Vaccines Dengue Tetravalent Vaccine

Application. Animal Models in Preclinical Evaluation of sanofi pasteur Flavivirus Vaccines Dengue Tetravalent Vaccine Animal Models in Preclinical Evaluation of sanofi pasteur Flavivirus Vaccines Dengue Tetravalent Vaccine Application Jean LANG M.D., Ph.D. avp R&D sanofi pasteur Dengue R&D Program Leader Fondation Merieux

More information

Cent Gardes Conference: HIV Vaccines. Organized by Fondation Mérieux Les Pensières Center for Global Health Veyrier du Lac - France

Cent Gardes Conference: HIV Vaccines. Organized by Fondation Mérieux Les Pensières Center for Global Health Veyrier du Lac - France Cent Gardes Conference: HIV Vaccines Organized by Fondation Mérieux Les Pensières Center for Global Health Veyrier du Lac - October 6th to 8th, 2017 Steering Committee Members Françoise Barré-Sinoussi

More information

Update on Vaccine Regulation: Expediting vaccine development. Phil Krause FDA/CBER/OVRR

Update on Vaccine Regulation: Expediting vaccine development. Phil Krause FDA/CBER/OVRR Update on Vaccine Regulation: Expediting vaccine development Phil Krause FDA/CBER/OVRR Challenges in vaccine development High cost of development relative to typical profits US markets are often dependent

More information

GSK s RSV vaccine product development overview

GSK s RSV vaccine product development overview GSK s RSV vaccine product development overview Introduction GSK maternal and paediatricrsv programs are in early stage of development (Phase I/II) For both programs, GSK is targeting a global development

More information

Are booster immunisations needed for lifelong hepatitis B immunity?

Are booster immunisations needed for lifelong hepatitis B immunity? Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B immunity, following meeting in Florence in October 1998 To date there are no data to support

More information

Dr Ch. Martin Infectious Diseases CHU Saint Pierre, Brussels

Dr Ch. Martin Infectious Diseases CHU Saint Pierre, Brussels Dr Ch. Martin Infectious Diseases CHU Saint Pierre, Brussels Yellow Fever Incubation: 3 6 days Symptoms: asymptomatic, flu symptoms, mild icteric haemorragic fever Mortality: 20 60% 170 000 severe cases/y,

More information

HIV Vaccine Conference

HIV Vaccine Conference HIV Vaccine Conference The B cell response to HIV and HIV vaccines: From broadly neutralizing to non-neutralizing antibodies In memory of Dr. Charles Mérieux Organized by Fondation Mérieux Les Pensières

More information

CD40L-Adjuvanted DNA/MVA SIV Vaccine Enhances Protection. Against Neutralization Resistant Mucosal SIV Infection

CD40L-Adjuvanted DNA/MVA SIV Vaccine Enhances Protection. Against Neutralization Resistant Mucosal SIV Infection JVI Accepted Manuscript Posted Online 4 February 2015 J. Virol. doi:10.1128/jvi.03527-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 CD40L-Adjuvanted DNA/MVA SIV Vaccine

More information

Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239

Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239 University of Massachusetts Medical School escholarship@umms Preventive and Behavioral Medicine Publications and Presentations Preventive and Behavioral Medicine 1-23-2009 Immunization with single-cycle

More information

Planning, Priority Setting, and Budget Development for NIH AIDS Research

Planning, Priority Setting, and Budget Development for NIH AIDS Research Planning, Priority Setting, and Budget Development for NIH AIDS Research Robert W. Eisinger, Ph.D. Office of AIDS Research s of Health Focus of Presentation Overview of OAR Priority Setting Process Budget

More information

Heterotypic Protection and Induction of a Broad Heterotypic Neutralization Response by Rotavirus-Like Particles

Heterotypic Protection and Induction of a Broad Heterotypic Neutralization Response by Rotavirus-Like Particles JOURNAL OF VIROLOGY, June 1999, p. 4813 4822 Vol. 73, No. 6 0022-538X/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Heterotypic Protection and Induction of a Broad

More information

Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV mac 239

Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV mac 239 Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV mac 239 Bin Jia 1, Sharon K. Ng 1, M. Quinn DeGottardi 1, Michael Piatak Jr. 2, Eloísa Yuste

More information

Start Date* Sites Description

Start Date* Sites Description HVTN 076 17 HVTN HVTN 084 100 HVTN HVTN 085 90 HVTN HVTN 096 96 HVTN IPPOX EuroVacc GSID USMHRP HVTN 098 94 HVTN Inovio clade B AIDSVAX B/E clade C NYVAC clade C PENNVAX-GP IL-12 adjuvant September-11

More information

Systems Biology and Animal Models: STRIDE

Systems Biology and Animal Models: STRIDE Systems Biology and Animal Models: STRIDE Michael G Katze, Ph.D. presentation to Eighth Comparative Medicine Resource Directors Meeting May 10th, 2010 Questions What Pandemics Are We Currently Experiencing?

More information

NASDAQ:NVAX Novavax, Inc. All rights reserved.

NASDAQ:NVAX Novavax, Inc. All rights reserved. Novavax vaccine induced improved immune responses against homologous and drifted A(H3N2) viruses in older adults compared to egg-based, high-dose, influenza vaccine World Vaccine Congress April 4, 2018

More information

Anti-addictive Drug Vaccine Platform

Anti-addictive Drug Vaccine Platform Anti-addictive Drug Vaccine Platform Brian J. Kelly, Ph.D. Cornell Center for Technology Enterprise and Commercialization June 21, 2012 Winning the War Strategy Use Gene Transfer Vectors to Develop Effective

More information

IL-12 and GM-CSF in DNA/MVA Immunizations against HIV-1 CRF12_BF Nef Induced T-Cell Responses With an Enhanced Magnitude, Breadth and Quality

IL-12 and GM-CSF in DNA/MVA Immunizations against HIV-1 CRF12_BF Nef Induced T-Cell Responses With an Enhanced Magnitude, Breadth and Quality IL-12 and GM-CSF in DNA/MVA Immunizations against HIV-1 CRF12_BF Nef Induced T-Cell Responses With an Enhanced Magnitude, Breadth and Quality Ana María Rodríguez, María Fernanda Pascutti., Cynthia Maeto.,

More information

Antivirals and Vaccines: What s old and new in HSV-2 treatment

Antivirals and Vaccines: What s old and new in HSV-2 treatment Antivirals and Vaccines: What s old and new in HSV-2 treatment Christine Johnston, MD, MPH Last Updated: January 19, 2018 uwptc@uw.edu uwptc.org 206-685-9850 Importance of HSV: Why pursue a vaccine? Prevention

More information

Mosaic vaccines elicit CD8 + T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys

Mosaic vaccines elicit CD8 + T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys Mosaic vaccines elicit CD + T lymphocyte responses that fer enhanced immune coverage of diverse HIV strains in monkeys 21 Nature America, Inc. All rights reserved. Sampa Santra 1, Hua-Xin Liao 2, Ruijin

More information

EPIDEMIOLOGICAL STUDIES

EPIDEMIOLOGICAL STUDIES EPIDEMIOLOGICAL STUDIES EPIDEMIOLOGIC STUDIES EPIDEMIOLOGIC STUDIES 8 Clinical Trial sites in Brasil (NICHD) Transfusion recipient study (NHLBI) Prospective study in Brasil (Yale) Natural history population

More information

NIH Public Access Author Manuscript Nature. Author manuscript; available in PMC 2013 October 25.

NIH Public Access Author Manuscript Nature. Author manuscript; available in PMC 2013 October 25. NIH Public Access Author Manuscript Published in final edited form as: Nature. 2013 April 25; 496(7446): 469 476. doi:10.1038/nature12053. Co-evolution of a broadly neutralizing HIV-1 antibody and founder

More information

Role of a ZIKV CHIM in vaccine evaluation. Anna Durbin Johns Hopkins Bloomberg School of Public Health WHO Zika Workshop, Geneva 2 June 2017

Role of a ZIKV CHIM in vaccine evaluation. Anna Durbin Johns Hopkins Bloomberg School of Public Health WHO Zika Workshop, Geneva 2 June 2017 Role of a ZIKV CHIM in vaccine evaluation Anna Durbin Johns Hopkins Bloomberg School of Public Health WHO Zika Workshop, Geneva 2 June 2017 1 ZIKV congenital syndrome There is increasing evidence from

More information

Live oral vaccine approaches to typhoid and paratyphoid vaccines

Live oral vaccine approaches to typhoid and paratyphoid vaccines Live oral vaccine approaches to typhoid and paratyphoid vaccines Myron M. (Mike) Levine, M.D., D.T.P.H. Center for Vaccine Development. University of Maryland School of Medicine, Baltimore, MD, USA 8 th

More information

Eradication of HIV Bonaventura Clotet Hospital Universitàri Germans Trias i Pujol Badalona. Barcelona. Catalonia

Eradication of HIV Bonaventura Clotet Hospital Universitàri Germans Trias i Pujol Badalona. Barcelona. Catalonia Eradication of HIV Bonaventura Clotet Hospital Universitàri Germans Trias i Pujol Badalona. Barcelona. Catalonia Dr Bonaventura Clotet Transparency declaration I have served during the past 2 years as

More information

Questions and answers: HVTN 078 vaccine study

Questions and answers: HVTN 078 vaccine study 1. What is the HVTN 078 study? Version 2 Last updated March 11, 2011 HVTN 078 is the name of a clinical trial to test the safety and immune response of 2 experimental HIV vaccines. The experimental vaccines

More information

Immunotypes of a Quaternary Site of HIV-1 Vulnerability and Their Recognition by Antibodies

Immunotypes of a Quaternary Site of HIV-1 Vulnerability and Their Recognition by Antibodies JOURNAL OF VIROLOGY, May 2011, p. 4578 4585 Vol. 85, No. 9 0022-538X/11/$12.00 doi:10.1128/jvi.02585-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Immunotypes of a Quaternary

More information

High Dose Inactivated Influenza Vaccines. Robert L. Atmar, M.D. Baylor College of Medicine WHO Meeting January 2013

High Dose Inactivated Influenza Vaccines. Robert L. Atmar, M.D. Baylor College of Medicine WHO Meeting January 2013 High Dose Inactivated Influenza Vaccines Robert L. Atmar, M.D. Baylor College of Medicine WHO Meeting January 2013 Increased (High) Dose IVV A Brief History Dose response for immunogenicity & injection

More information

Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors

Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors JOURNAL OF VIROLOGY, June 2007, p. 6548 6562 Vol. 81, No. 12 0022-538X/07/$08.00 0 doi:10.1128/jvi.02749-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Dissecting the Neutralizing

More information

Proposing an NIH HIV/AIDS Clinical Trials Network Study: Background, Guidance & Additional Resources. NIH HIV/AIDS Clinical Trials Networks:

Proposing an NIH HIV/AIDS Clinical Trials Network Study: Background, Guidance & Additional Resources. NIH HIV/AIDS Clinical Trials Networks: Proposing an NIH HIV/AIDS Clinical Trials Network Study: Background, Guidance & Additional Resources This guidance document for current and future network behavioral and social science researchers as they

More information

BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY

BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY This presentation includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which

More information

Of mice and men: practical approaches to malaria vaccine discovery and development

Of mice and men: practical approaches to malaria vaccine discovery and development Of mice and men: practical approaches to malaria vaccine discovery and development --> The consequences of the screen employed to identify a parasite molecule as a «major vaccine candidate «Or the problem

More information

Antibody gene transfer for HIV immunoprophylaxis

Antibody gene transfer for HIV immunoprophylaxis Antibody gene transfer for HIV immunoprophylaxis Alejandro B Balazs & Anthony P West Jr Antibody gene transfer, which involves the delivery of genes that encode potent, broadly neutralizing antibodies

More information

Diversifying the Pipeline of Product Concepts for an HIV Vaccine. RFP Overview and Guidelines

Diversifying the Pipeline of Product Concepts for an HIV Vaccine. RFP Overview and Guidelines Diversifying the Pipeline of Product Concepts for an HIV Vaccine RFP Overview and Guidelines 1 Table of Contents 1. Introduction. 3 2. Background a. Foundation s HIV Vaccine Strategy 3 b. CAVD Framework..

More information

Chapter 14 Part One Biotechnology and Industry: Microbes at Work

Chapter 14 Part One Biotechnology and Industry: Microbes at Work Chapter 14 Part One Biotechnology and Industry: Microbes at Work Objectives: After reading Chapter 14, you should understand How biotechnology has resulted in numerous pharmaceutical products to help lessen

More information

Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Published in WER 4 June, 2010

Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Published in WER 4 June, 2010 Polio vaccines and polio immunization in the pre-eradication era: WHO position paper Published in WER 4 June, 2010 Epidemiology & Background Poliomyelitis (polio) is an acute communicable disease of humans

More information

Prophylactic HPV vaccines: next generations

Prophylactic HPV vaccines: next generations New Trends in Tumor Virology: Annecy Jan 19, 2010 Prophylactic HPV vaccines: next generations Lutz Gissmann l.gissmann@dkfz.de Conflict of interest LG is a consultant to GSK and Sanofi Pasteur MSD and,

More information

Principles of Vaccination

Principles of Vaccination Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the

More information

HBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board

HBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board HBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board 2 nd Hepatitis Cure and Eradication Meeting 11 12 November 2015 Declaration of Interest

More information

Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo

Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo The MIT Faculty has made this article openly available. Please share how this access benefits you. Your

More information

Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ

Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ www.micropathology.com info@micropathology.com Micropathology Ltd Tel 24hrs: +44 (0) 24-76 323222 Fax / Ans: +44 (0) 24-76 - 323333 University of Warwick Science Park, Venture Centre, Sir William Lyons

More information

Developmental Toxicity Study Designs for Preventive Vaccines: Issues and Challenges

Developmental Toxicity Study Designs for Preventive Vaccines: Issues and Challenges Developmental Toxicity Study Designs for Preventive Vaccines: Issues and Challenges Marion F. Gruber, Ph.D. Office of Vaccines Research and Review CBER/FDA HESI Annual Meeting June 8, 2011 Alexandria,

More information

Overview of role of immunologic markers in HIV diagnosis

Overview of role of immunologic markers in HIV diagnosis Overview of role of immunologic markers in HIV diagnosis Savita Pahwa, M.D. Departments of Microbiology & Immunology and Pediatrics University of Miami, Miller School of Medicine, Miami, Florida Background:

More information

DNA Vaccines against Human Immunodeficiency Virus Type 1 in the Past Decade

DNA Vaccines against Human Immunodeficiency Virus Type 1 in the Past Decade CLINICAL MICROBIOLOGY REVIEWS, Apr. 2004, p. 370 389 Vol. 17, No. 2 0893-8512/04/$08.00 0 DOI: 10.1128/CMR.17.2.370 389.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. DNA

More information

* Corresponding author: Tel.: ; Fax:

* Corresponding author: Tel.: ; Fax: JVI Accepted Manuscript Posted Online 8 February 2017 J. Virol. doi:10.1128/jvi.02182-16 Copyright 2017 American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

More information

WHO Preferred Product Characteristics for Next-Generation Influenza Vaccines

WHO Preferred Product Characteristics for Next-Generation Influenza Vaccines WHO Preferred Product Characteristics for Next-Generation Influenza Vaccines DEPARTMENT OF IMMUNIZATION, VACCINES AND BIOLOGICALS WHO preferred product characteristics for next generation influenza vaccines

More information

HVTN HIV Diagnostics Program

HVTN HIV Diagnostics Program HVTN HIV Diagnostics Program John Hural, Ph.D. Carissa Karg, MPH March 14, 2013 The HVTN is supported through a cooperative agreement with the National Institute of Allergy and Infectious Diseases 1 HIV

More information

Antigens and Immunogens

Antigens and Immunogens Background 1. Medical Importance of Immune System (vaccines, immunodeficiency diseases, hypersensitivity) 2. How the Immune System Works (innate & adaptive immune mech., B/T cells, Abs, Cytokines) 2. Cells

More information

Received 13 July 2000/Accepted 27 January 2001

Received 13 July 2000/Accepted 27 January 2001 JOURNAL OF VIROLOGY, May 2001, p. 4165 4175 Vol. 75, No. 9 0022-538X/01/$04.00 0 DOI: 10.1128/JVI.75.9.4165 4175.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Vaccine-Elicited

More information

HIV-1 vaccine immunogen design strategies

HIV-1 vaccine immunogen design strategies Mann and Ndung u Virology Journal (2015) 12:3 DOI 10.1186/s12985-014-0221-0 REVIEW Open Access HIV-1 vaccine immunogen design strategies Jaclyn K Mann 1,2 and Thumbi Ndung u 1,2,3,4* Abstract An effective

More information

Lines of Defense. Immunology, Immune Response, and Immunological Testing. Immunology Terminology

Lines of Defense. Immunology, Immune Response, and Immunological Testing. Immunology Terminology Immunology, Immune Response, and Immunological Testing Lines of Defense If the First and Second lines of defense fail, then the Third line of defense is activated. B and T lymphocytes undergo a selective

More information

ABSTRACT. n engl j med 369;22 nejm.org november 28,

ABSTRACT. n engl j med 369;22 nejm.org november 28, The new england journal of medicine established in 1812 november 28, 2013 vol. 369 no. 22 Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Scott M. Hammer, M.D., Magdalena E. Sobieszczyk, M.D., M.P.H., Holly

More information

Vaccins anti-vih: un défi! Vaccins anti VIH : un développement complexe.et extraordinairement difficile!

Vaccins anti-vih: un défi! Vaccins anti VIH : un développement complexe.et extraordinairement difficile! Vaccins anti-vih: un défi! Vaccins anti VIH : un développement complexe.et extraordinairement difficile! Marc Girard, Professeur honoraire Université Paris Diderot et Institut Pasteur, Membre émérite de

More information